[1]施昌盛,杨 庆,肖池金,等.血清高迁移率组蛋白B1、可溶性晚期糖基化终末产物受体、脱氧核糖核酸酶与TACE早期疗效相关性研究[J].介入放射学杂志,2016,(08):677-681.
　SHI Chang-sheng,YANG Qing,XIAO Chi-jin,et al.Correlation study between HMGB1, sRAGE, DNase and the short-term efficacy of TACE [J].journal interventional radiology,2016,(08):677-681.
点击复制

血清高迁移率组蛋白B1、可溶性晚期糖基化终末产物受体、脱氧核糖核酸酶与TACE早期疗效相关性研究 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年08期
页码:
677-681
栏目:
肿瘤介入
出版日期:
2016-08-25

文章信息/Info

Title:
Correlation study between HMGB1, sRAGE, DNase and the short-term efficacy of TACE

作者:
施昌盛;  杨 庆;  肖池金;  虞希祥;  郑冰汝;  李 成
Author(s):
SHI Chang-sheng;  YANG Qing;  XIAO Chi-jin;  YU Xi-xiang;  ZHENG Bing-ru; LI Cheng
Department of Interventional Radiology, Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province 325200, China
关键词:
【关键词】 肝癌;  肝动脉化疗栓塞;  高迁移率组蛋白B1;  可溶性晚期糖基化终末产物受体;  脱氧核糖核酸酶;  疗效
文献标志码:
A
摘要:
【摘要】 目的 探讨原发性肝癌患者血清高迁移率组蛋白B1（HMGB1）、人可溶性晚期糖基化终末产物（sRAGE）、脱氧核糖核酸酶（DNase）对TACE近期疗效的评估价值。 方法 对收住的42例患者（共计56次TACE治疗）分别在TACE术前、术后24 h采集外周静脉血标本,用ELISA法检测外周血清中HMGB1、sRAGE、DNase的表达水平。根据mRECIST标准进行TACE术后疗效评估,将完全缓解+部分缓解+疾病稳定的病例归为获益组,疾病进展者归为无效组。比较TACE术前、术后,获益组及无效组之间的血清HMGB1、sRAGE、Dnase的表达水平,并进行统计学分析。 结果 TACE术前与术后24 h血清HMGB1、sRAGE、DNase表达水平比较差异有显著统计学意义（ P =0.003, P =000, P =0.001）,且术后较术前呈升高趋势。56例次TACE中,24例次为稳定（SD）,2例次部分缓解（PR）,30例次为肿瘤进展（PD）,将SD和PR患者归为获益组（ n =26）,PD患者为无效组( n =30)。在TACE术前,获益组与无效组血清HMGB1、DNase表达水平比较差异无统计意义（ P =0.395, P =0.091）；在TACE术后24 h,血清HMGB1、DNase在获益组和无效组对比差异也无统计学意义（ P =0.354, P =0.182）。而sRAGE在获益组与无效组之间的表达水平在术前差异无统计学意义（ P =0.143）,而在术后24 h,两组间sRAGE表达水平差异有统计学意义（ P =0.030）。 结论 ①TACE术后血清HMGB1、sRAGE、DNase表达水平较术前升高；②中晚期肝癌患者外周血清中sRAGE与TACE疗效相关,可以作为TACE治疗肝癌疗效早期评估的指标。

参考文献/References:

［1］ Kohles N, Nagel D, Jungst D, et al. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients［J］. BMC Cancer, 2011, 11: 202.
［2］ Naglova H, Bucova M. HMGB1 and its physiological and pathological roles［J］. Bratisl Lek Listy, 2012, 113: 163-171.
［3］ Dong YD, Cui L, Peng CH, et al. Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo［J］. Oncol Rep, 2013, 29: 87-94.
［4］ Song do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period［J］. Clin Mol Hepatol, 2012, 18: 258-267.
［5］ Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma［J］. Semin Liver Dis, 2010, 30: 52-60.
［6］ 乔彬彬, 虞希祥, 王舒婷, 等. TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析［J］. 介入放射学杂志, 2015, 24: 349-353.
［7］ Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis［J］. Gut, 2001, 48: 251-259.
［8］ Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival［J］. Hepatology, 2003, 37: 429-442.
［9］ Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients［J］. Gastroenterology, 2006, 131: 461-469.
［10］ Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial［J］. Lancet, 2002, 359: 1734-1739.
［11］ 庄利萍, 于 璐, 杨 倩, 等. HMGB1 RAGE 蛋白在肝癌中的表达及临床意义［J］. 河北医学, 2015, 21: 377-382.
［12］ Shrivastava S, Mansure JJ, Almajed W, et al. The role of HMGB1 in radio-resistance of bladder cancer［J］. Mol Cancer Ther, 2016, 15: 471-479
［13］ Luo J, Chen J, He L. Mir-129-5p attenuates irradiation-induced autophagy and decreases radioresistance of breast cancer cells by targeting HMGB1［J］. Med Sci Monit, 2015, 21: 4122-4129.
［14］ 王婷婷, 韩菲菲, 陈国千. 高迁移率族蛋白B1与消化系统恶性肿瘤［J］. 医学研究生学报, 2013, 26: 1083-1087.
［15］ Lehner J, Wittwer C, Fersching D, et al. Methodological and preanalytical evaluation of an HMGB1 immunoassay［J］. Anticancer Res, 2012, 32: 2059-2062.
［16］ 王新军, 周少龙, 付旭东, 等. 人脑胶质瘤组织HMGB1表达临床意义初步分析［J］. 中华肿瘤防治杂志, 2014, 21: 1339-1342.
［17］ Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma［J］. Digest Liver Dis, 2008, 40: 446-452.
［18］ Delgado-Lopez F, Rojas A. RAGE at tumor microenvironment. looking at tumor-associated macrophages［J］. Zhongguo Fei Ai Za Zhi, 2015, 18: 725-726.
［19］ Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation［J］. J Transl Med, 2009, 7: 17.
［20］ Kostova N, Zlateva S, Ugrinova I, et al. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors［J］. Mol Cell Biochem, 2010, 337: 251-258.
［21］ Stoetzer OJ, Fersching DM, Salat C, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy［J］. Tumour Biol, 2013, 34: 81-90.
［22］ Patel PS, Patel BP, Rawal RM, et al. Evaluation of serum alkaline DNase activity in treatment monitoring of head and neck cancer patients［J］. Tumour Biol, 2000, 21: 82-89.

相似文献/References:

[1]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[2]卢丽琴,陈方宏,袁建华,等.晚期肝癌伴门脉癌栓的介入治疗[J].介入放射学杂志,1996,(03):136.
[3]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合ＣＴ引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
　,,et al.Ｓｅｑｕｅｎｔｉａｌ ｔｒｅａｔｍｅｎｔ ｗｉｔｈ ＴＡＣＥ ａｎｄ ＣＴｇｕｉｄｅｄ ＲＦＡ ｆｏｒ ｓｍａｌｌ ａｎｄ ｍｏｄｅｒａｔｅ ｓｉｚｅｄ ＨＣＣ [J].journal interventional radiology,2012,(08):301.
[4]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(08):968.
[5]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(08):1010.
[6]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(08):75.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(08):78.
[8]赵许亚,周 石.TACE联合经皮瘤内注射碘油吡柔比星乳剂治疗中晚期肝癌疗效分析[J].介入放射学杂志,2012,(08):675.
　ZHAO Xu- ya,ZHOU Shi.. Transcatheter artery chemoembolization combined with percutaneous intratumoral injection of Lipiodol emulsion of pirarubicin for advanced hepatocellular carcinomas： an analysis of clinical efficacy[J].journal interventional radiology,2012,(08):675.
[9]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(08):682.
[10]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(08):1035.
[11]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(08):322.
[12]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(08):348.
[13]陈付文,郑春生,黄柿兵,等.肝动脉化疗栓塞联合射频消融治疗大肝癌的临床观察[J].介入放射学杂志,2015,(08):684.
　CHEN Fu- wen,ZHENG Chun- sheng,HUANG Shi- bing,et al.TACE combined with RFA for the treatment of massive primary hepatocellular carcinomas： observation of clinical efficacy and safety[J].journal interventional radiology,2015,(08):684.
[14]薛幼华,芮冶昊,黄薛菲,等.快速康复理念在肝癌患者行肝动脉化疗栓塞中的应用[J].介入放射学杂志,2016,(01):78.
　XUE You- hua,RUI Ye- hao,HUANG Xue- fei,et al.The application of fast recovery concept in treating patients with liver cancer by using transcatheter arterial chemoembolization[J].journal interventional radiology,2016,(08):78.
[15]蒋力平,刘兵元,张立鹏.乙肝相关肝癌患者行TACE术后HBV再激活的临床研究 [J].介入放射学杂志,2018,27(02):171.
　JIANG Liping,LIU Bingyuan,ZHANG Lipeng.Clinical study of hepatitis B virus reactivation in patients with hepatitis B- related liver cancer after receiving transcatheter arterial chemoembolization therapy[J].journal interventional radiology,2018,27(08):171.
[16]周旭林,满沐苒,王璐璐,等.肝动脉化疗栓塞联合放疗治疗中晚期肝癌疗效与安全性的荟萃分析 [J].介入放射学杂志,2019,28(05):428.
　ZHOU Xulin,MAN Muran,WANG Lulu,et al.TACE combined with radiotherapy for the treatment of mid- stage and advanced liver cancers： a meta- analysis of its clinical efficacy and safety[J].journal interventional radiology,2019,28(08):428.

备注/Memo

备注/Memo:
（收稿日期：2016-01-05）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-08-23